Functional and Economic Impact of INOCA and Influence of Coronary Microvascular Dysfunction. 2021

Christopher L Schumann, and Roshin C Mathew, and John-Henry L Dean, and Yang Yang, and Pelbreton C Balfour, and Peter W Shaw, and Austin A Robinson, and Michael Salerno, and Christopher M Kramer, and Jamieson M Bourque
Division of Cardiovascular Medicine and the Cardiac Imaging Center, University of Virginia Health System, Charlottesville, Virginia, USA.

This study sought to better characterize the quality of life and economic impact in patients with symptoms of ischemia and no obstructive coronary disease (INOCA) and to identify the influence of coronary microvascular dysfunction (CMD). Patients with INOCA have a high symptom burden and an increased incidence of major adverse cardiac events. CMD is a frequent cause of INOCA. The morbidity associated with INOCA and CMD has not been well-characterized. Sixty-six patients with INOCA underwent stress cardiac magnetic resonance with calculation of myocardial perfusion reserve (MPR); MPR 2.0 to 2.4 was considered borderline-reduced (possible CMD) and MPR <2.0 was defined as reduced (definite CMD). Subjects completed quality of life questionnaires to assess the morbidity and economic impact of INOCA. Questionnaire results were compared between INOCA patients with and without CMD. In addition, logistic regression was used to determine the predictors of CMD within the INOCA population. The prevalence of definite CMD was 24%. Definite or borderline CMD was present in 59% (MPR ≤2.4). Patients with INOCA reported greater physical limitation, angina frequency, and reduced quality of life compared to referent stable coronary artery disease and acute myocardial infarction populations. In addition, Patients with INOCA reported frequent time missed from work and work limitations, suggesting a substantial economic impact. No difference was observed in reported symptoms between INOCA patients with and without CMD. Glomerular filtration rate and body-mass index were significant predictors of CMD in multivariable regression analysis. INOCA is associated with high morbidity similar to other high-risk cardiac populations, and work limitations reported by Patients with INOCA suggest a substantial economic impact. CMD is a common cause of INOCA but is not associated with increased morbidity. These results suggest that there is significant symptom burden in the INOCA population regardless of etiology.

UI MeSH Term Description Entries
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Christopher L Schumann, and Roshin C Mathew, and John-Henry L Dean, and Yang Yang, and Pelbreton C Balfour, and Peter W Shaw, and Austin A Robinson, and Michael Salerno, and Christopher M Kramer, and Jamieson M Bourque
March 2024, Cardiovascular revascularization medicine : including molecular interventions,
Christopher L Schumann, and Roshin C Mathew, and John-Henry L Dean, and Yang Yang, and Pelbreton C Balfour, and Peter W Shaw, and Austin A Robinson, and Michael Salerno, and Christopher M Kramer, and Jamieson M Bourque
April 2024, Journal of the American Heart Association,
Christopher L Schumann, and Roshin C Mathew, and John-Henry L Dean, and Yang Yang, and Pelbreton C Balfour, and Peter W Shaw, and Austin A Robinson, and Michael Salerno, and Christopher M Kramer, and Jamieson M Bourque
February 2023, Clinical cardiology,
Christopher L Schumann, and Roshin C Mathew, and John-Henry L Dean, and Yang Yang, and Pelbreton C Balfour, and Peter W Shaw, and Austin A Robinson, and Michael Salerno, and Christopher M Kramer, and Jamieson M Bourque
January 2015, Nature reviews. Cardiology,
Christopher L Schumann, and Roshin C Mathew, and John-Henry L Dean, and Yang Yang, and Pelbreton C Balfour, and Peter W Shaw, and Austin A Robinson, and Michael Salerno, and Christopher M Kramer, and Jamieson M Bourque
January 2022, Frontiers in endocrinology,
Christopher L Schumann, and Roshin C Mathew, and John-Henry L Dean, and Yang Yang, and Pelbreton C Balfour, and Peter W Shaw, and Austin A Robinson, and Michael Salerno, and Christopher M Kramer, and Jamieson M Bourque
July 2021, Journal of cardiovascular imaging,
Christopher L Schumann, and Roshin C Mathew, and John-Henry L Dean, and Yang Yang, and Pelbreton C Balfour, and Peter W Shaw, and Austin A Robinson, and Michael Salerno, and Christopher M Kramer, and Jamieson M Bourque
January 2021, Clinical hemorheology and microcirculation,
Christopher L Schumann, and Roshin C Mathew, and John-Henry L Dean, and Yang Yang, and Pelbreton C Balfour, and Peter W Shaw, and Austin A Robinson, and Michael Salerno, and Christopher M Kramer, and Jamieson M Bourque
September 2017, Cardiovascular revascularization medicine : including molecular interventions,
Christopher L Schumann, and Roshin C Mathew, and John-Henry L Dean, and Yang Yang, and Pelbreton C Balfour, and Peter W Shaw, and Austin A Robinson, and Michael Salerno, and Christopher M Kramer, and Jamieson M Bourque
April 2020, Minerva cardioangiologica,
Christopher L Schumann, and Roshin C Mathew, and John-Henry L Dean, and Yang Yang, and Pelbreton C Balfour, and Peter W Shaw, and Austin A Robinson, and Michael Salerno, and Christopher M Kramer, and Jamieson M Bourque
May 2021, Arteriosclerosis, thrombosis, and vascular biology,
Copied contents to your clipboard!